April 1st 2025
Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
Southern Florida Psychiatry Conference
November 21-22, 2025
Register Now!
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
View More
Optimizing Care for Patients With Tardive Dyskinesia
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Severe Mental Illness on the Decline in Youngsters--An 'Unexpected' Finding
June 1st 2015Rates of severe mental illness in children and adolescents have dropped 16% since 1996, according to a new study. The lead author explains possible reasons for this surprising finding and concludes: "We're moving in the right direction!"
Listen
Brain Stimulation With ECT: Neuroscience Insights From an Old Treatment
January 22nd 2015Some recent breakthroughs, using newly developed neuroscience investigational tools, suggest that if research resources are available, we could soon make substantial advances in understanding the mechanism of action of ECT.
Read More
Art Therapy in a Patient With Bipolar Disorder: Pictures Speak More Than a Thousand Words
November 25th 2014Here: the case of a woman with bipolar disorder who was admitted for aggressive behavior and nonadherence to medications. Art therapy and pharmacotherapy played a pivotal role in her recovery.
Read More
Screening for Metabolic Syndrome in Bipolar Disorder
September 5th 2014It is absolutely essential that every person who has bipolar disorder be screened for risk factors related to metabolic syndrome and diabetes and traditional risk factors like overweight and eating habits. More in this podcast.
Listen
Rapid-Acting Antidepressants: Where Do We Stand with Ketamine?
September 5th 2014The lay press has focused a lot of attention on the use of ketamine as a potentially rapidly acting treatment for depression. But are psychiatrists really ready to offer ketamine as a treatment alternative for mood disorders? An expert weighs in.
Listen
A Novel Approach to Morbidity and Mortality Analysis in Psychiatry Residency
July 16th 2014Regulatory bodies that oversee hospitals and graduate medical education have begun to place an ever growing importance on patient safety and quality improvement, from which psychiatry is not immune. More in this case study.
Read More
Update on Mood Disorders in Later Life
June 17th 2014Mood disorders in older adults are neither inevitable nor particularly resistant to treatment. With attention to the special needs of older patients during evaluation, treatment, and follow up, clinicians can help many patients derive greater enjoyment from their later years.
Read More